Claims
- 1. A method for preventing or inhibiting the development of sensitization caused by chronic use of at least one dopaminergic agent, comprising administering to a mammal in need of the preventing or inhibiting at least one alpha2-adrenoceptor antagonist in an amount effective for the preventing or inhibiting.
- 2. The method according to claim 1, wherein the sensitization comprises dyskinesia seen in Parkinson's Disease after chronic treatment with L-dopa.
- 3. The method according to claim 1, wherein the at least one alpha2-adrenoceptor antagonist comprises one or more of atipamezole and pharmaceutically acceptable salts thereof.
- 4. The method according to claim 1, wherein the at least one alpha2-adrenoceptor antagonist comprises one or more of idazoxan and pharmaceutically acceptable salts thereof.
- 5. The method according to claim 1, wherein the at least one alpha2-adrenoceptor | antagonist comprises one or more of efaroxan and pharmaceutically acceptable salts thereof.
- 6. The method according to claim 1, wherein the at least one alpha2-adrenoceptor antagonist comprises one or more of 4-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-y1)-1H-imidazole and pharmaceutically acceptable salts thereof.
- 7. The method according to claim 1, wherein the at least one alpha2-adrenoceptor antagonist comprises at least one analog chosen from analogs of atipamezole, analogs of idazoxan, and analogs of efaroxan.
- 8. The method according to claim 1, wherein the at least one alpha2-adrenoceptor antagonist comprises at least one ester chosen from esters of atipamezole, esters of idazoxan, and esters of efaroxan.
- 9. A method for preventing or inhibiting the development of sensitization associated with the development of drug dependency, comprising administering to a mammal in need of the preventing or inhibiting at least one alpha2-adrenoceptor antagonist in an amount effective for the preventing or inhibiting.
- 10. A method for preventing or inhibiting the development of sensitisation caused by at least one dopaminergic agent administered at least twice, comprising administering to a mammal in need of the preventing or inhibiting at least one alpha2-adrenoceptor antagonist in an amount effective for the preventing or inhibiting.
Parent Case Info
[0001] This application claims the benefit of priority under 35 U.S.C. § 119(e) of U.S. provisional application No. 60 248,004, filed on Nov. 14, 2000, which is specifically incorporated herein by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60248004 |
Nov 2000 |
US |